APA (7th ed.) Citation

Millán, O., Rovira, J., Guirado, L., Espinosa, C., Budde, K., Sommerer, C., . . . Brunet, M. (2021). Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation. Clinical immunology, 229, . https://doi.org/10.1016/j.clim.2021.108792

Chicago Style (17th ed.) Citation

Millán, Olga, Jordi Rovira, Lluis Guirado, Cristina Espinosa, Klemens Budde, Claudia Sommerer, Gaston J. Piñeiro, Fritz Diekmann, and Mercè Brunet. "Advantages of Plasmatic CXCL-10 as a Prognostic and Diagnostic Biomarker for the Risk of Rejection and Subclinical Rejection in Kidney Transplantation." Clinical Immunology 229 (2021). https://doi.org/10.1016/j.clim.2021.108792.

MLA (9th ed.) Citation

Millán, Olga, et al. "Advantages of Plasmatic CXCL-10 as a Prognostic and Diagnostic Biomarker for the Risk of Rejection and Subclinical Rejection in Kidney Transplantation." Clinical Immunology, vol. 229, 2021, https://doi.org/10.1016/j.clim.2021.108792.